IL311999A - New modulators of EHMT1 and EHMT2 and their therapeutic use - Google Patents
New modulators of EHMT1 and EHMT2 and their therapeutic useInfo
- Publication number
- IL311999A IL311999A IL311999A IL31199924A IL311999A IL 311999 A IL311999 A IL 311999A IL 311999 A IL311999 A IL 311999A IL 31199924 A IL31199924 A IL 31199924A IL 311999 A IL311999 A IL 311999A
- Authority
- IL
- Israel
- Prior art keywords
- ehmt1
- ehmt2
- therapeutic use
- novel modulators
- modulators
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163256057P | 2021-10-15 | 2021-10-15 | |
| US202263390438P | 2022-07-19 | 2022-07-19 | |
| PCT/US2022/046761 WO2023064586A1 (en) | 2021-10-15 | 2022-10-14 | Novel modulators of ehmt1 and ehmt2 and therapeutic use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL311999A true IL311999A (en) | 2024-06-01 |
Family
ID=84357982
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL311999A IL311999A (en) | 2021-10-15 | 2022-10-14 | New modulators of EHMT1 and EHMT2 and their therapeutic use |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240368139A1 (https=) |
| EP (1) | EP4416143A1 (https=) |
| JP (1) | JP2024538128A (https=) |
| KR (1) | KR20240148310A (https=) |
| AU (1) | AU2022366869A1 (https=) |
| CA (1) | CA3234693A1 (https=) |
| IL (1) | IL311999A (https=) |
| MX (1) | MX2024004416A (https=) |
| WO (1) | WO2023064586A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116602242B (zh) * | 2023-05-08 | 2024-01-23 | 中国水产科学研究院珠江水产研究所 | 一种提高反季鱼苗成活率的方法 |
| WO2025155882A1 (en) * | 2024-01-19 | 2025-07-24 | Icahn School Of Medicine At Mount Sinai | G9a/glp degradation / disruption compounds and methods of use |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3270960A (en) | 1964-09-11 | 1966-09-06 | Sperry Rand Corp | Fluid sensor |
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| PL3442947T3 (pl) * | 2016-04-15 | 2023-10-02 | Epizyme, Inc. | Związki arylowe lub heteroarylowe podstawione aminą jako inhibitory ehmt1 i ehmt2 |
| US20200039998A1 (en) * | 2016-12-19 | 2020-02-06 | Epizyme, Inc. | Amine-substituted heterocyclic compounds as ehmt2 inhibitors and methods of use thereof |
| US20200113901A1 (en) * | 2017-03-31 | 2020-04-16 | Epizyme, Inc. | Methods of using ehmt2 inhibitors |
| CN110621316B (zh) * | 2017-04-21 | 2024-01-26 | Epizyme股份有限公司 | 用ehmt2抑制剂进行的组合疗法 |
| JP2021500326A (ja) * | 2017-10-18 | 2021-01-07 | エピザイム，インコーポレイティド | 血液障害の予防又は処置にｅｈｍｔ２阻害剤を使用する方法 |
| AU2018353139A1 (en) * | 2017-10-18 | 2020-06-04 | Epizyme, Inc. | Methods of using EHMT2 inhibitors in immunotherapies |
-
2022
- 2022-10-14 JP JP2024522501A patent/JP2024538128A/ja active Pending
- 2022-10-14 KR KR1020247016027A patent/KR20240148310A/ko active Pending
- 2022-10-14 MX MX2024004416A patent/MX2024004416A/es unknown
- 2022-10-14 US US18/701,092 patent/US20240368139A1/en active Pending
- 2022-10-14 AU AU2022366869A patent/AU2022366869A1/en active Pending
- 2022-10-14 IL IL311999A patent/IL311999A/en unknown
- 2022-10-14 CA CA3234693A patent/CA3234693A1/en active Pending
- 2022-10-14 WO PCT/US2022/046761 patent/WO2023064586A1/en not_active Ceased
- 2022-10-14 EP EP22802794.2A patent/EP4416143A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022366869A1 (en) | 2024-05-02 |
| KR20240148310A (ko) | 2024-10-11 |
| US20240368139A1 (en) | 2024-11-07 |
| MX2024004416A (es) | 2024-07-09 |
| EP4416143A1 (en) | 2024-08-21 |
| JP2024538128A (ja) | 2024-10-18 |
| WO2023064586A1 (en) | 2023-04-20 |
| CA3234693A1 (en) | 2023-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL287720A (en) | modulators of thr-in the cell and methods of using them | |
| IL305860A (en) | BCL6 proteolysis modulators and related methods of use | |
| IL292810A (en) | Therapeutic compounds and methods of use | |
| PT3983064T (pt) | Moduladores de cot e respetivos métodos de utilização | |
| EP4090658A4 (en) | THERAPEUTIC AGENTS AND METHODS OF TREATMENT | |
| IL320805B1 (en) | Medical uses of tirazepate | |
| IL317543A (en) | Kinase modulators and methods of using them | |
| IL311999A (en) | New modulators of EHMT1 and EHMT2 and their therapeutic use | |
| IL299245A (en) | LAIR-1 binding agents and methods of using them | |
| GB2596661B (en) | Therapeutic and prophylactic use of microorganisms | |
| GB202019475D0 (en) | Therapeutic compounds and their use | |
| IL310096A (en) | CD38 modulators and methods of using them | |
| GB202108572D0 (en) | Therapeutic compounds and their use | |
| GB2613900B (en) | Novel compounds and methods of use thereof | |
| ZA202207188B (en) | Liquid tasimelteon formulations and methods of use thereof | |
| IL313081A (en) | New HDAC inhibitors and their medical use | |
| GB201909573D0 (en) | Modulation of T cell cytotoxicity and related therapy | |
| GB202005599D0 (en) | Modulation of t cell cytotoxicity and related therapy | |
| HK40115486A (en) | Novel modulators of ehmt1 and ehmt2 and therapeutic use thereof | |
| IL319132A (en) | New FSHR modulators and their uses | |
| IL308683A (en) | Peptides and methods of use | |
| EP4243816A4 (en) | KINASE MODULATORS AND METHODS OF USE THEREOF | |
| GB202012482D0 (en) | Novel compounds and therapeutic uses thereof | |
| GB202105874D0 (en) | COVID-19 Therapeutic antennapedia-antibody molecules and methods of use thereof | |
| IL320820A (en) | Therapeutic combinations of captopril and ventocalix |